Previsión
El precio objetivo medio de los analistas es de 10,02 € (+186,29 %). La mediana es de 9,11 € (+160,29 %).
| Comprar |
11 |
| Mantener |
3 |
| Vender |
7 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
MannKind achieves positive phase‑1b results for inhaled nintedanib in IPF
MannKind reports positive topline results from the randomized, double‑blind phase‑1b study INFLO‑1 of inhaled nintedanib as a dry powder in patients with idiopathic pulmonary fibrosis (IPF). The 27‑patient study showed no serious adverse events, no drug‑related gastrointestinal side effects, no bronchospasms and no discontinuations or dose reductions; cough was mostly mild and transient. Overall, IPF patients received about 450 inhalations; combined with phase‑1a, 48 people were treated, 18 of them with IPF. The global phase‑2 study INFLO‑2 to further evaluate nintedanib DPI is currently recruiting and is expected to enroll around 210 participants. » Más en de.investing.com
Wells Fargo upgrades MannKind after pediatric Afrezza approval, calls commercial potential a “show‑me story”
Wells Fargo raised its price target on MannKind to $11 and kept an Overweight rating, citing FDA approval of Afrezza for patients aged 6 and older and supportive INHALE‑1 data. The approval expands Afrezza’s market to pediatric patients and caregivers. MannKind also highlighted potential near‑term upside from up to $35 million in development milestones, a 10% royalty on net sales and its role as sole manufacturer of Tyvaso DPI. » Más en finance.yahoo.com
MannKind completes patient recruitment for INFLO‑1 and starts global phase‑2 for Nintedanib DPI
MannKind has completed randomization of patients in the phase‑1b trial INFLO‑1 and has enrolled the first patient in the global phase‑2 trial INFLO‑2 for Nintedanib DPI. INFLO‑1 evaluates safety, tolerability and pharmacokinetics; results are expected in Q3 2026. INFLO‑2 aims to recruit about 210 participants at roughly 85 sites in a randomized, double‑blind 1:1:1 design over 12 weeks (with a 24‑week open extension) for dose finding and safety assessment. » Más en de.investing.com
MannKind: shareholders re-elect nine directors, approve compensation and auditor
At the annual general meeting, shareholders re-elected all nine nominated MannKind directors and voted in an advisory capacity to approve the board’s compensation. Deloitte & Touche was confirmed as the independent auditor for the fiscal year ending December 31, 2026. In quarterly results, MannKind reported a 15% revenue rise to $90 million, mainly driven by FUROSCIX following the acquisition of scPharmaceuticals, but missed the EPS forecast of -$0.01 with a non-GAAP net loss of $0.02 per share. » Más en de.investing.com
MannKind records Q1 revenue up 15% and sees three near-term regulatory catalysts
MannKind reported Q1 2026 revenue of $90 million (up 15% year-over-year), driven by the integration of FUROSCIX; the adjusted non-GAAP result showed a loss of $6.9 million. Management emphasizes strategic diversification away from a one-product model and identifies three imminent value drivers: Afrezza Pediatrics (PDUFA May 29), the FUROSCIX ReadyFlow autoinjector (PDUFA July 26), and nintedanib DPI with topline data in Q3 and the start of Phase 2 recruitment. The partnership with United Therapeutics for Ralinepag DPI was also expanded, including an upfront payment and milestones, and the revenue outlook for FUROSCIX in 2026 remains $110–120 million. » Más en de.investing.com
Dividendos históricos Dividendos
Todas las métricas de dividendos Todas las métricasEn 2022, MannKind Co. ya ha pagado 7,52 € en dividendos. El último pago fue en septiembre de 2022.
Datos financieros
En el último trimestre, MannKind Co. tuvo unos ingresos de 89,94 M € y un beneficio neto de -20,5 M €
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 89,94 M | 28,51 % |
| Beneficio bruto | 69,18 M | 31,09 % |
| Beneficio neto | -20,5 M | 401,33 % |
| EBITDA | -4,73 M | 131,10 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 1147,59 M € |
Número de acciones | 321,64 M |
Máximo/mínimo de 52 semanas | 5,93 € - 2,03 € |
| Dividendos | No |
Beta | 1,09 |
Ratio P/E | -16,62 |
Ratio PEG | 0,16 |
Ratio P/B | -33,64 |
Ratio P/S | 3,05 |
Perfil de la empresa
MannKind Corporation, una empresa biofarmacéutica, se centra en el desarrollo y la comercialización de productos terapéuticos inhalados para enfermedades endocrinas y huérfanas del pulmón en Estados Unidos. Ofrece Afrezza, una insulina inhalada utilizada para mejorar el control glucémico en adultos con diabetes. También promociona Thyquidity entre endocrinólogos pediátricos y de adultos, así como otros profesionales sanitarios, para el tratamiento del hipotiroidismo. La compañía tiene un acuerdo de licencia y colaboración con United Therapeutics Corporation. También mantiene un acuerdo con NRx Pharmaceuticals para desarrollar una formulación en polvo seco de ZYESAMI (aviptadil), una forma sintética del péptido intestinal vasoactivo humano que ayuda a proteger las células frente a afecciones inflamatorias. MannKind Corporation se constituyó en 1991 y tiene su sede en Westlake Village, California.
| Nombre | MannKind Co. |
| CEO | Michael E. Castagna |
| Sede | Danbury,
ca Estados Unidos |
| Sitio web | |
| Sector | Materiales |
| Industria | Productos químicos |
| Salida a bolsa | 28/07/2004 |
| Empleados | 592 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NASDAQ | MNKD |
Frankfurt | NNFN.F |
Düsseldorf | NNFN.DU |
SIX | NNFN.SW |
München | NNFN.MU |